Compare Stocks: CCCC, TSHA, INBX, and RXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.76 +0.5%	$3.92	$1.69 ▼ $5.17	$462.59M	2.94	2.68 million shs	2.36 million shs
INBX Inhibrx Biosciences	$121.17 -0.9%	$96.73	$26.19 ▼ $155.29	$1.78B	3.66	311,969 shs	192,159 shs
RXRX Recursion Pharmaceuticals	$3.63 +5.5%	$3.33	$2.77 ▼ $7.18	$1.94B	1.07	18.08 million shs	29.01 million shs
TSHA Taysha Gene Therapies	$5.60 +0.5%	$6.08	$2.71 ▼ $7.30	$1.82B	1.19	2.83 million shs	2.11 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	-1.32%	-8.78%	+3.60%	-2.86%	+46.09%
INBX Inhibrx Biosciences	-2.17%	-1.35%	+45.26%	+40.51%	+339.78%
RXRX Recursion Pharmaceuticals	+1.78%	0.00%	+3.93%	+3.61%	-25.70%
TSHA Taysha Gene Therapies	-1.24%	-6.54%	-10.16%	+1.27%	+92.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.76 +0.5%	$3.92	$1.69 ▼ $5.17	$462.59M	2.94	2.68 million shs	2.36 million shs
INBX Inhibrx Biosciences	$121.17 -0.9%	$96.73	$26.19 ▼ $155.29	$1.78B	3.66	311,969 shs	192,159 shs
RXRX Recursion Pharmaceuticals	$3.63 +5.5%	$3.33	$2.77 ▼ $7.18	$1.94B	1.07	18.08 million shs	29.01 million shs
TSHA Taysha Gene Therapies	$5.60 +0.5%	$6.08	$2.71 ▼ $7.30	$1.82B	1.19	2.83 million shs	2.11 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	-1.32%	-8.78%	+3.60%	-2.86%	+46.09%
INBX Inhibrx Biosciences	-2.17%	-1.35%	+45.26%	+40.51%	+339.78%
RXRX Recursion Pharmaceuticals	+1.78%	0.00%	+3.93%	+3.61%	-25.70%
TSHA Taysha Gene Therapies	-1.24%	-6.54%	-10.16%	+1.27%	+92.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.60	Moderate Buy	$7.67	104.17% Upside
INBX Inhibrx Biosciences	2.50	Moderate Buy	$197.50	62.94% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	119.32% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	129.04% Upside

Current Analyst Ratings Breakdown

Latest CCCC, TSHA, INBX, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/24/2026	INBX Inhibrx Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$245.00
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
7/21/2026	TSHA Taysha Gene Therapies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $13.00
7/17/2026	CCCC C4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RXRX Recursion Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	TSHA Taysha Gene Therapies	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$11.00
6/30/2026	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
6/30/2026	TSHA Taysha Gene Therapies	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$12.00 ➝ $15.00
6/24/2026	TSHA Taysha Gene Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	TSHA Taysha Gene Therapies	Pivotal Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.95M	12.85	N/A	N/A	$2.01 per share	1.87
INBX Inhibrx Biosciences	$1.30M	1,372.44	N/A	N/A	($3.60) per share	-33.67
RXRX Recursion Pharmaceuticals	$74.68M	26.34	N/A	N/A	$1.71 per share	2.15
TSHA Taysha Gene Therapies	$9.77M	185.93	N/A	N/A	$1.19 per share	4.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	11/13/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest CCCC, TSHA, INBX, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.45	5.45
INBX Inhibrx Biosciences	12.58	5.07	5.07
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
INBX Inhibrx Biosciences	82.46%
RXRX Recursion Pharmaceuticals	89.06%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	5.60%
INBX Inhibrx Biosciences	18.26%
RXRX Recursion Pharmaceuticals	6.65%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	150	123.03 million	116.14 million	Optionable
INBX Inhibrx Biosciences	166	14.72 million	12.03 million	Optionable
RXRX Recursion Pharmaceuticals	400	535.34 million	499.74 million	Optionable
TSHA Taysha Gene Therapies	180	325.83 million	314.50 million	Optionable

CCCC, TSHA, INBX, and RXRX Headlines

Recent News About These Companies

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4 at 8:00 AM | globenewswire.com

Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA

August 26, 2026 | marketbeat.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - Should You Sell?

August 20, 2026 | marketbeat.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages

August 18, 2026 | marketbeat.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's Why

August 13, 2026 | marketbeat.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings

August 12, 2026 | marketbeat.com

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

August 12, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Q2 Earnings Call Highlights

August 11, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 11, 2026 | marketbeat.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

Taysha Taps Catalent for Potential Commercial Manufacturing of TSHA-102

August 3, 2026 | finance.yahoo.com

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

August 3, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, TSHA, INBX, and RXRX Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$3.76 +0.02 (+0.53%)

As of 04:00 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Inhibrx Biosciences NASDAQ:INBX

$121.17 -1.09 (-0.89%)

As of 04:00 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.63 +0.19 (+5.52%)

As of 04:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Taysha Gene Therapies NASDAQ:TSHA

$5.60 +0.03 (+0.54%)

As of 04:00 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, TSHA, INBX, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, TSHA, INBX, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, TSHA, INBX, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, TSHA, INBX, and RXRX Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Inhibrx Biosciences NASDAQ:INBX

Recursion Pharmaceuticals NASDAQ:RXRX

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, TSHA, INBX, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, TSHA, INBX, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, TSHA, INBX, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, TSHA, INBX, and RXRX Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Inhibrx Biosciences NASDAQ:INBX

Recursion Pharmaceuticals NASDAQ:RXRX

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools